Ghent, Belgium, April 1, 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces its contribution to the advancement of CYRS1542, a novel GSPT1 molecular glue degrader developed by Cyrus Therapeutics, into Phase 1 clinical development.
Cyrus Therapeutics received Investigational New Drug (IND) approvals from both the US FDA and the Korean Ministry of Food and Drug Safety (MFDS) in 2025, enabling the initiation of first-in-human clinical studies.
As part of this program, Ardena was responsible for the formulation development of oral dosage forms and the GMP manufacturing of clinical trial material. This work supported the transition from preclinical development into clinical evaluation, ensuring consistent product performance and readiness for clinical use.
“We are pleased to support Cyrus Therapeutics in bringing CYRS1542 into clinical development,” said Ardena’s CEO, Jeremie Trochu. “Our teams collaborated closely on formulation and GMP manufacturing to deliver a drug product suitable for first-in-human studies.”
This milestone highlights the importance of robust formulation and manufacturing capabilities in progressing innovative oncology therapies into the clinic.
